Down Syndrome-Associated Alzheimer's Disease
What is Down Syndrome-Associated Alzheimer's Disease?
Down syndrome-associated Alzheimer's disease is a form of dementia that affects adults with Down syndrome at much higher rates than the general population. People with Down syndrome have an extra copy of chromosome 21. This chromosome contains the APP gene, which produces amyloid protein in the brain. Having three copies instead of two leads to excess amyloid buildup over time.
This extra amyloid protein creates plaques in the brain that damage neurons and lead to Alzheimer's disease. Most adults with Down syndrome develop Alzheimer's pathology by age 40. Symptoms typically appear between ages 50 and 60, which is 20 to 30 years earlier than in the general population. Nearly all people with Down syndrome will show brain changes associated with Alzheimer's by their mid-40s.
Early detection is critical because cognitive assessment in people with Down syndrome can be challenging. Blood tests that measure brain proteins like phosphorylated tau-217 can now detect Alzheimer's changes before symptoms appear. This allows families and care teams to plan ahead and start interventions earlier.
Symptoms
- Memory loss that disrupts daily activities and familiar routines
- Difficulty with previously learned tasks like dressing or eating
- Changes in personality, mood, or behavior patterns
- Increased confusion or disorientation in familiar places
- Loss of language skills or difficulty communicating
- Withdrawal from social activities and interactions
- Changes in sleep patterns or increased daytime sleepiness
- Loss of motor skills or changes in walking ability
- Seizures, which affect about 40% of people with this condition
- Decline in self-care abilities and independence
Many people with Down syndrome show no obvious symptoms in the early stages. Brain changes begin years or even decades before memory and thinking problems become noticeable. This makes regular monitoring especially important for early detection.
Concerned about Down Syndrome-Associated Alzheimer's Disease? Check your levels.
Screen for 1,200+ health conditions
Causes and risk factors
The primary cause is having three copies of chromosome 21 instead of two. This extra chromosome contains the APP gene, which tells the body to make amyloid precursor protein. With three copies of this gene, people with Down syndrome produce about 50% more amyloid protein throughout their lives. This excess protein forms sticky plaques in the brain that damage and kill neurons. Over decades, this damage leads to the memory loss and cognitive decline seen in Alzheimer's disease.
Age is the most significant risk factor. Nearly everyone with Down syndrome develops Alzheimer's brain changes by their 40s. Other factors that may influence when symptoms appear include sex, with women potentially at higher risk. APOE gene variants, which affect Alzheimer's risk in the general population, also play a role. Lifestyle factors like physical activity, social engagement, and cardiovascular health may influence disease progression, though more research is needed in this population.
How it's diagnosed
Diagnosis traditionally relied on observing cognitive and behavioral changes over time. This approach has limitations because people with Down syndrome have varying baseline cognitive abilities. Standardized cognitive tests designed for the general population often don't work well in this group. Family members and caregivers who know the person well are critical for identifying subtle changes in function and behavior.
Blood tests now offer a more objective way to detect Alzheimer's disease before symptoms appear. Phosphorylated tau-217, or p-tau217, is a brain protein that appears in blood when neurons are damaged. This test can identify Alzheimer's pathology years before clinical symptoms emerge. Rite Aid offers p-tau217 testing as an add-on to help families monitor brain health in adults with Down syndrome. Early detection allows care teams to plan interventions and support services before significant decline occurs.
Treatment options
- Cholinesterase inhibitors like donepezil may help with memory and thinking in some people
- Memantine can help manage moderate to severe symptoms in certain cases
- Structured daily routines and familiar environments support independence longer
- Regular physical activity supports brain health and may slow decline
- Social engagement and meaningful activities maintain quality of life
- Treatment of co-occurring conditions like thyroid problems, sleep apnea, and hearing loss
- Occupational therapy helps maintain self-care skills and adapt to changes
- Speech therapy supports communication as language skills decline
- Caregiver education and support services are essential for families
- Seizure medications if epilepsy develops
Need testing for Down Syndrome-Associated Alzheimer's Disease? Add it to your panel.
- Simple blood draw at your nearest lab
- Results in days, not weeks
- Share results with your doctor
Frequently asked questions
People with Down syndrome have three copies of chromosome 21 instead of two. This chromosome contains the APP gene, which produces amyloid protein that builds up in the brain. Having an extra copy means the body produces about 50% more of this protein throughout life. Over decades, this excess protein forms plaques that damage brain cells and cause Alzheimer's disease.
Brain changes associated with Alzheimer's usually begin by age 40 in people with Down syndrome. Most people show these changes by their mid-40s. Symptoms typically become noticeable between ages 50 and 60, which is 20 to 30 years earlier than in the general population.
Phosphorylated tau-217 is a brain protein that appears in blood when neurons are damaged by Alzheimer's disease. When brain cells die, this protein leaks into the bloodstream where it can be measured. P-tau217 testing can detect Alzheimer's pathology years before symptoms appear. This early detection is especially valuable in people with Down syndrome, where traditional cognitive testing can be challenging.
The disease affects people with Down syndrome much earlier and progresses somewhat differently. It appears 20 to 30 years younger than typical Alzheimer's disease. Seizures are more common, affecting about 40% of people compared to 10% in the general population. The genetic cause is also clearer, with the extra chromosome 21 directly leading to excess amyloid production.
Some medications used for Alzheimer's in the general population may help people with Down syndrome. Donepezil and other cholinesterase inhibitors can improve memory and thinking in some cases. Memantine may help with moderate to severe symptoms. Research is ongoing to understand which treatments work best in this population.
Regular monitoring should begin around age 40 when brain changes typically start. Annual cognitive and behavioral assessments are recommended to catch early changes. Blood tests like p-tau217 can be done periodically to detect pathology before symptoms appear. Your care team can recommend a screening schedule based on individual needs and family concerns.
Regular physical activity supports brain health and may slow disease progression. Social engagement and mentally stimulating activities help maintain cognitive function longer. Structured daily routines provide stability and support independence. Treating other health conditions like thyroid problems, sleep apnea, and hearing loss is also important for brain health.
Look for changes from the person's usual abilities and behaviors. This might include difficulty with previously mastered tasks like dressing or eating. Watch for personality changes, increased confusion, or withdrawal from activities they once enjoyed. Keep track of sleep patterns, communication abilities, and mood changes. Family members who know the person well are best positioned to notice subtle early changes.
No additional genetic testing is needed because the diagnosis requires an existing Down syndrome diagnosis. People with Down syndrome already have the genetic factor that causes increased Alzheimer's risk. Diagnosis focuses on detecting when Alzheimer's pathology begins through blood tests, cognitive assessment, and monitoring for symptoms. Some people may benefit from APOE gene testing, which can provide additional risk information.
Many resources exist to support families caring for someone with Down syndrome and Alzheimer's disease. Specialized programs offer memory care adapted for people with intellectual disabilities. Occupational and speech therapy help maintain function and communication. Caregiver support groups connect families facing similar challenges. Respite care services provide breaks for primary caregivers.